Cover Image
市場調查報告書

全球細胞診斷市場考察,機會分析,市場佔有率,預測

Global Tissue Diagnostics Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 363174
出版日期 內容資訊 英文 140 Pages
商品交期: 請詢問到貨日
價格
Back to Top
全球細胞診斷市場考察,機會分析,市場佔有率,預測 Global Tissue Diagnostics Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022
出版日期: 2016年07月11日 內容資訊: 英文 140 Pages
簡介

全球細胞診斷市場,預計2022年擴大到48億1190萬美元。預計市場2016年∼2022年以8.6%的年複合成長率成長。

本報告提供全球細胞診斷市場相關調查分析,市場概要,市場決策要素,各部門分析,各地區分析,企業簡介等系統性資訊。

第1章 簡介

第2章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 參數分析
  • 主要市場考察
  • 競爭資訊
  • 價值鏈分析
  • 主要的購買標準
  • 策略性建議
  • 策略性結論

第3章 市場決策要素

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 市場課題

第4章 各部門分析

  • 親市場
  • 子區隔市場
  • 替代市場

第5章 市場區隔

  • 各技術
  • 各疾病
  • 各產品
  • 各終端用戶

第6章 競爭情形

  • 市場佔有率
  • 策略

第7章 各地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 其他
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 其他
  • 其他地區

第8章 企業簡介

  • ROCHE
  • ABBOTT LABORATORIES, INC.
  • AGILENT TECHNOLOGIES
  • BIOGENEX LABORATORIES
  • BIO SB.
  • CELL SIGNALLING TECHNOLOGY, INC.
  • QIAGEN
  • BECTON DICKINSON & COMPANY
  • ALERE
  • DIAGENIC
  • MEDTRONIC INC
  • STRYKER
  • BIOMERIUX
  • PROMETHEUS LABORATORIES
  • DANAHER CORPORATION
目錄
Product Code: HBI-1291015

The global tissue diagnostics market is expected to reach $4811.9 million by 2022 growing at 8.6% CAGR during 2016-2022. In regional outlook, market is divided into North America, Europe, Asia Pacific and rest of the world. North America dominates the global tissue diagnostics market, which accounts for around 40.7% of the global market share. The major reason boosting the North American region upward is the rising patient's awareness level, presence of technologically advanced products, and the rising healthcare expenditure. The United States and Canada are the major countries in North American region that boost the market growth. Asia Pacific is the fastest growing global tissue diagnostics market, due to rapid improvement in healthcare infrastructure, presence of sophisticated healthcare facilities in the developed markets of Australia and Japan. Asia Pacific is one of the most profitable and revenue generating market for major market players in the forecast period. China, Japan, South Korea and Australia are the major countries in Asia Pacific region. Europe is showing positive growth due to rising prevalence of cancer in this region, favorable government policies related to tissue diagnostics and increasing geriatric population. Rest of the world is showing positive growth rate for the global tissue diagnostics market in the forecast period. Brazil and Middle East is the major countries in the Rest of the world region.

Global tissue diagnostics market is segmented on the basis of technology, disease, products, end users and regional outlook. In technology segment, market is divided into immunohistochemistry, in situ hybridization, digital pathology and workflow management, magneto encephalograph and special staining. In disease segment, market is divided into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung carcinoma and other disease. In product segment, market is divided into instrument and consumables. In end user segment, market is divided into hospitals, pharmaceuticals, research laboratories, contract research organization and others.

Global tissue diagnostics market is rising rapidly and is demanding for effective tissue diagnostic procedures majorly due to increasing prevalence of chronic diseases, such as liver cancer, brain cancer, lung cancer, colorectal, breast cancer, cervical cancers, cardiovascular disorders, malaria, and diabetes and many more. Apart from this, the increased use of biomarkers for disease diagnosis has a positive impact on the market for global tissue diagnostics in the forecast period. Biomarkers help to evaluate the physiological, pharmacological and disease processes, and are broadly used for various clinical studies in the area of genomics, proteomics, metabolomics and transcriptomics. The ability of biomarkers to aid in the purpose of disease prognosis, elucidation of pathways is majorly affected by the disease and identification of individuals which is likely to respond to specific therapeutic interventions, which will result in its better utilization during the forecast period.

Some of the major market players are Danaher corporation, Medtronic Inc., GE healthcare, Ventana medical Systems, Thermo fisher scientific, Asuragen Inc., Johnson & Johnson, Span Diagnostics, Cadwell laboratories Inc., veridex, Xcyton diagnostic, Sekisui diagnostic, etc. Acquisition, mergers and expansions are the key strategies adopted by the market players to sustain in the market.

Table of Contents

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. MARKET DEFINITION AND SCOPE
  • 2.2. KEY FINDINGS
  • 2.3. PARAMETRIC ANALYSIS
    • 2.3.1. PREVALENCE & INCIDENCE RATE OF CANCER
    • 2.3.2. PREVALENCE & INCIDENCE RATE OF NEURO-DEGENERATIVE DISEASES
    • 2.3.3. HOSPITAL AND RESEARCH CENTER ACROSS GEOGRAPHIES
    • 2.3.4. RISE IN DISPOSABLE INCOMES IN EMERGING ECONOMIES
    • 2.3.5. HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
  • 2.4. KEY MARKET INSIGHTS
    • 2.4.1. TOP 3 EMERGING COUNTRIES
    • 2.4.2. TOP 3 REVENUE GENERATING SEGMENTS
    • 2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS
    • 2.4.4. EP 2764124 A4: DIAGNOSTIC ASSAY FOR TISSUE TRANSPLANTATION PATENT ANALYSIS STATUS
      • 2.4.4.1. EP 2764091 A4: DIAGNOSTIC METHOD FOR CONNECTIVE TISSUE ANT ITS APPLICATION
      • 2.4.4.2. EP 2764091 A4: DIAGNOSTIC METHOD FOR CONNECTIVE TISSUE ANT ITS APPLICATION
      • 2.4.4.3. EP 2761268 A4: ULTRA-RAPID DIAGNOSTIC TISSUE PREPARATION AS AN ALTERNATIVE TO FROZEN SECTION
    • 2.4.5. R&D SCENARIO IN BRAIN MONITORING MARKET
      • 2.4.5.1. R&D IN ADVANCE TISSUE DIAGNOSTICS
      • 2.4.5.2. R&D IN IN-VITRO DIAGNOSTICS
      • 2.4.5.3. R&D IN CANCER THERAPEUTICS
  • 2.5. COMPETITIVE INTELLIGENCE
    • 2.5.1. MARKET SHARE ANALYSIS
    • 2.5.2. TOP WINNING STRATEGIES
    • 2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
  • 2.6. VALUE CHAIN ANALYSIS
  • 2.7. KEY BUYING CRITERIA
  • 2.8. STRATEGIC RECOMMENDATION
  • 2.9. STRATEGIC CONCLUSIONS

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. GLOBAL RISE IN IN-VITRO DIAGNOSTICS ENABLES TISSUE DIAGNOSTIC MARKET TO GROW FAST
    • 3.1.2. GLOBAL RISE IN CANCER DIAGNOSTICS AND TREATMENT
    • 3.1.3. GLOBAL RISE IN ADOPTION OF DIAGNOSTICS GIVING RISE TO GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.1.4. TECHNOLOGICAL ADVANCEMENT ENABLES TO EXPAND GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.1.5. INNOVATION GIVING RISE TO GROWTH OF GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.1.6. GLOBAL INCREASE IN HEALTHCARE EXPENDITURE
    • 3.1.7. RISE IN ADOPTION OF PERSONALIZED MEDICINES IS DRIVING THE GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.1.8. FUNDING FROM GOVERNMENT AND PRIVATE PLAYERS TO BOOST GLOBAL TISSUE DIAGNOSTIC MARKET
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. HIGH COST OF TISSUE DIAGNOSTICS AFFECTS GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.2.2. REIMBURSEMENT ISSUES CREATES HURDLES IN THE GROWTH OF GLOBAL TISSUE DIAGNOSTIC MARKET
  • 3.3. MARKET CHALLENGES
    • 3.3.1. CREATING AWARENESS FOR GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.3.2. GLOBAL ECONOMIC SLOWDOWN MAY AFFECT THE GLOBAL BRAIN MONITORING MARKET
    • 3.3.3. STRINGENT GOVERNMENT REGULATIONS AND POLICIES MAY AFFECT GLOBAL TISSUE DIAGNOSTIC MARKET
  • 3.4. MARKET OPPORTUNITIES
    • 3.4.1. FDA APPROVALS GIVING RISE TO SIGNIFICANT SCOPE IN GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.4.2. ADVANCEMENTS IN DIAGNOSTICS CREATING SCOPE FOR GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.4.3. RISING CANCER DISEASES CREATES DEMAND FOR GLOBAL TISSUE DIAGNOSTIC MARKET

4. SECTOR ANALYSIS

  • 4.1. PARENT MARKET
  • 4.2. SUB-SEGMENT MARKET
  • 4.3. ALTERNATIVE MARKET

5. MARKET SEGMENTATION

  • 5.1. GLOBAL TISSUE DIAGNOSTIC MARKET BY TECHNOLOGY, 2014-2022,($ MILLIONS)
    • 5.1.1. GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY PRODUCT, 2014-2022,($ MILLIONS)
    • 5.1.2. GLOBAL IN SITU HYBRIDIZATION MARKET, 2014-2022,($ MILLIONS)
    • 5.1.3. GLOBAL DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT MARKET, 2014-2022,($ MILLIONS)
    • 5.1.4. GLOBAL MAGNETOENCEPHALOGRAPH MARKET, 2014-2022,($ MILLIONS)
    • 5.1.5. GLOBAL SPECIAL STAINING MARKET, 2014-2022,($ MILLIONS)
  • 5.2. GLOBAL TISSUE DIAGNOSTIC MARKET BY DISEASE, 2014-2022,($ MILLIONS)
    • 5.2.1. GLOBAL BREAST CANCER MARKET, 2014-2022,($ MILLIONS)
    • 5.2.2. GLOBAL GASTRIC CANCER MARKET , 2014-2022,($ MILLIONS)
    • 5.2.3. GLOBAL LYMPHOMA MARKET, 2014-2022,($ MILLIONS)
    • 5.2.4. GLOBAL PROSTATE CANCER MARKET, 2014-2022,($ MILLIONS)
    • 5.2.5. GLOBAL NON-SMALL CELL LUNG CARCINOMA MARKET, 2014-2022,($ MILLIONS)
    • 5.2.6. GLOBAL OTHER DISEASE MARKET, 2014-2022,($ MILLIONS)
  • 5.3. GLOBAL TISSUE DIAGNOSTIC MARKET BY PRODUCT, 2014-2022,($ MILLIONS)
    • 5.3.1. GLOBAL INSTRUMENT MARKET, 2014-2022,($ MILLIONS)
    • 5.3.2. GLOBAL CONSUMABLES MARKET, 2014-2022,($ MILLIONS)
  • 5.4. GLOBAL TISSUE DIAGNOSTIC MARKET BY END USER, 2014-2022,($ MILLIONS)
    • 5.4.1. GLOBAL HOSPITALS MARKET, 2014-2022,($ MILLIONS)
    • 5.4.2. GLOBAL PHARMACEUTICALS MARKET, 2014-2022,($ MILLIONS)
    • 5.4.3. GLOBAL RESEARCH LABORATORIES MARKET, 2014-2022,($ MILLIONS)
    • 5.4.4. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET, 2014-2022,($ MILLIONS)
    • 5.4.5. GLOBAL OTHERS MARKET, 2014-2022,($ MILLIONS)

6. COMPETITIVE LANDSCAPE

  • 6.1. MARKET SHARE
  • 6.2. STRATEGY - AN ANALYSIS ACROSS TIERS

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.1.1. UNITED STATES (U.S.) TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.1.2. CANADA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
  • 7.2. EUROPE TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.1. UNITED KINGDOM (UK) TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.2. FRANCE TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.3. GERMANY TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.4. SPAIN TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.5. ITALY TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.6. ROE TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
  • 7.3. ASIA PACIFIC TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.3.1. INDIA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.3.2. CHINA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.3.3. JAPAN TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.3.4. KOREA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.3.5. AUSTRALIA TISSUE MONITORING MARKET T, 2014-2022,($MILLIONS)
    • 7.3.6. ROAPAC TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
  • 7.4. REST OF THE WORLD TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.4.1. LATIN AMERICA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.4.2. MENA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.4.3. AFRICA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)

8. COMPANY PROFILES

  • 1. ROCHE
  • 2. ABBOTT LABORATORIES, INC.
  • 3. AGILENT TECHNOLOGIES
  • 4. BIOGENEX LABORATORIES
  • 5. BIO SB.
  • 6. CELL SIGNALLING TECHNOLOGY, INC.
  • 7. QIAGEN
  • 8. BECTON DICKINSON & COMPANY
  • 9. ALERE
  • 10. DIAGENIC
  • 11. MEDTRONIC INC
  • 12. STRYKER
  • 13. BIOMERIUX
  • 14. PROMETHEUS LABORATORIES
  • 15. DANAHER CORPORATION.

LIST OF TABLES

  • 1. GLOBAL TISSUE DIAGNOSTIC MARKET BY TECHNOLOGY, 2014-2022,($ MILLIONS)
  • 2. GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY PRODUCT, 2014-2022,($ MILLIONS)
  • 3. GLOBAL IN SITU HYBRIDIZATION MARKET, 2014-2022,($ MILLIONS)
  • 4. GLOBAL DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT MARKET, 2014-2022,($ MILLIONS)
  • 5. GLOBAL MAGNETOENCEPHALOGRAPH MARKET, 2014-2022,($ MILLIONS)
  • 6. GLOBAL SPECIAL STAINING MARKET, 2014-2022,($ MILLIONS)
  • 7. GLOBAL TISSUE DIAGNOSTIC MARKET BY DISEASE, 2014-2022,($ MILLIONS)
  • 8. GLOBAL BREAST CANCER MARKET, 2014-2022,($ MILLIONS)
  • 9. GLOBAL GASTRIC CANCER MARKET , 2014-2022,($ MILLIONS)
  • 10. GLOBAL LYMPHOMA MARKET, 2014-2022,($ MILLIONS)
  • 11. GLOBAL PROSTATE CANCER MARKET, 2014-2022,($ MILLIONS)
  • 12. GLOBAL NON-SMALL CELL LUNG CARCINOMA MARKET, 2014-2022,($ MILLIONS)
  • 13. GLOBAL OTHER DISEASE MARKET, 2014-2022,($ MILLIONS)
  • 14. GLOBAL TISSUE DIAGNOSTIC MARKET BY PRODUCT, 2014-2022,($ MILLIONS)
  • 15. GLOBAL INSTRUMENT MARKET, 2014-2022,($ MILLIONS)
  • 16. GLOBAL CONSUMABLES MARKET, 2014-2022,($ MILLIONS)
  • 17. GLOBAL TISSUE DIAGNOSTIC MARKET BY END USER, 2014-2022,($ MILLIONS)
  • 18. GLOBAL HOSPITALS MARKET, 2014-2022,($ MILLIONS)
  • 19. GLOBAL PHARMACEUTICALS MARKET, 2014-2022,($ MILLIONS)
  • 20. GLOBAL RESEARCH LABORATORIES MARKET, 2014-2022,($ MILLIONS)
  • 21. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET, 2014-2022,($ MILLIONS)
  • 22. GLOBAL OTHERS MARKET, 2014-2022,($ MILLIONS)

LIST OF FIGURES

  • 1. UNITED STATES (U.S.) TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 2. CANADA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 3. UNITED KINGDOM (UK) TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 4. FRANCE TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 5. GERMANY TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 6. SPAIN TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 7. ITALY TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 8. ROE TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 9. INDIA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 10. CHINA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 11. JAPAN TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 12. KOREA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 13. AUSTRALIA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 14. ROAPAC TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 15. LATIN AMERICA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 16. MENA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 17. AFRICA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
Back to Top